Relationship between MLH1/MSH2 expression and prognosis of patients with sporadic colorectal cancer / 肿瘤

ABSTRACT

Objective: To investigate the expressions of mismatch repair gene MutL homolog 1 (MLH1) and MutS homolog 2 (MSH2) in stage II-III sporadic colorectal adenocarcinoma tissues and their clinical signifiance. Methods: The specimens and follow-up data of 490 patients with sporadic colorectal cancer were collected after surgery from January 2014 to April 2016 in Nanjing Hospital of Chinese Medicine. The expressions of MLH1 and MSH2 in colorectal cancer were detected by immunohistochemistry. The relationships of MLH1 and MSH2 expressions with the clinical characteristics and prognosis of patients with colorectal cancer were analyzed. Results: The deletion rate of MLH1/MSH2 expression in colorectal cancer tissues was 20.41% (100/490). The MLH1/MSH2 deletion was correlated with tumor differentiation, location, mucus and lymph node metastasis (all P < 0.05). MLH1/MSH2 deletion mainly occurred in the patients with poorly differentiation, right colon, mucus, and 1-3 lymph nodes metastasis. The disease-free survival (DFS) time of patients with MLH1/MSH2 deletion was longer than that of patients with MLH1/MSH2 normal expression (33.9 months vs 30.4 months, P < 0.001). The prognosis of patients with right colon tumor, poor differentiation, TNM stage III, metastatic lymph nodes more than four, mucus, positive margin and MLH1/MSH2 normal expression was poor (all P < 0.05). The tumor differentiation, tumor location, mucus, surgical margin and expression of MLH1/MSH2 were independent prognostic factors for the patients with stage II - III sporadic colorectal cancer. Conclusion: There is MLH1/MSH2 deletion in stage II - III sporadic colorectal cancer tissues, and it is an independent prognostic factor in patients with colorectal cancer.